Endometrial Neoplasm

Background

Endometrial cancer (EC), a type of endometrial neoplasm, is a malignancy originating from the epithelial lining of the uterus. It is the most common gynecological cancer in developed countries and ranks as the fourth most common cancer among women in the United States.^[1] Endometrioid adenocarcinoma represents the majority (60%) of Type 1 endometrial tumors.^[2]

Biological Basis

The development of endometrial neoplasm is influenced by both environmental and genetic factors. A family history of endometrial cancer is associated with an increased risk, suggesting a role for inherited genetic predispositions.^[1]A significant genetic predisposition occurs in individuals with Lynch syndrome (also known as Hereditary Nonpolyposis Colorectal Cancer, HNPCC), which is caused by inherited mutations inDNA mismatch repair genes.^{[3], [4], [5]}Estimates of heritability for endometrial cancer have suggested a notable genetic component, particularly in younger women.^[6]and familial clustering has been observed even when accounting for factors like obesity.^[7] However, for sporadic cases, which constitute the vast majority of endometrial cancers, a twin study suggested a low genetic contribution.^[8]Genome-wide association studies (GWAS) have been instrumental in identifying common genetic variants associated with endometrial cancer risk. One such locus identified is within theHNF1B gene, located on chromosome 17q12.^[9] The common variant rs4430796 in HNF1Bhas shown a significant association with reduced endometrial cancer risk.^{[1], [9]} The HNF1B gene, also known as TCF2, LFB3 MODY5, and VHNF1, encodes a homeodomain-containing transcription factor involved in regulating gene expression.^[9] The risk associated with rs4430796 appears to be consistent across both Type 1 and Type 2 tumors, and the association is particularly strengthened for the endometrioid histological subtype.^{[1], [9]}

Clinical Relevance

The genetic insights into endometrial neoplasm have significant clinical implications. For women with Lynch syndrome, the lifetime risk of developing endometrial cancer is substantially elevated, ranging from 50–60%, compared to 2–3% in the general population.^[1]Furthermore, women with this inherited predisposition tend to develop the disease approximately 15 years earlier than individuals in the general population.^[1] Identifying genetic susceptibility loci, such as HNF1B, contributes to a better understanding of risk factors and may inform future strategies for screening and prevention.

Social Importance

Endometrial cancer represents a considerable public health burden globally, given its prevalence as the most common gynecological malignancy. Its impact extends to a large population of women, necessitating extensive research efforts to improve understanding, prevention, and treatment. International collaborations, such as the Endometrial Cancer Association Consortium (ECAC) and the Collaborative Oncological Gene-environment Study (COGS) initiative, involve researchers and samples from numerous countries, including the UK, USA, Belgium, Germany, Norway, Sweden, and Australia.^[10]These large-scale studies, often involving multiethnic populations, are crucial for identifying genetic polymorphisms and other factors that influence susceptibility to endometrial cancer across diverse ancestries.^[1]

Methodological and Statistical Constraints

Research into endometrial neoplasm faces several methodological and statistical challenges that influence the interpretation and generalizability of findings. Many genome-wide association studies (GWAS) have historically suffered from insufficient statistical power due to limited sample sizes, with some studies having less than 1% power to detect associations, particularly for variants with smaller effects.^[1] This underpowering can lead to an inability to identify novel genetic loci or accurately estimate effect sizes, potentially contributing to the winner’s curse phenomenon where initial effect estimates are inflated.^[1] Furthermore, issues such as considerable sample overlap across different GWAS datasets can introduce biases into meta-analyses if not properly accounted for.^[11] The presence of heterogeneity between studies, as evidenced by statistics like I2, also complicates the combination of results and may necessitate advanced statistical methods like Mendelian randomization to adjust for potential pleiotropy and ensure robust causal inferences.^[9]

Generalizability and Phenotypic Heterogeneity

A significant limitation in understanding endometrial neoplasm genetics is the restricted generalizability of findings, primarily due to a predominant focus on populations of European ancestry. Studies have explicitly noted a lack of statistically significant associations in other ethnicities, indicating that genetic discoveries may not translate universally across diverse populations.^[1] The classification of study participants based on “race” rather than genetically informed ancestry also presents a limitation, as race is a social construct and not an ideal population descriptor in genetic research, potentially obscuring true genetic differences.^[12]Additionally, the phenotypic definition of endometrial neoplasm can introduce heterogeneity; while some studies focus on specific histological subtypes like endometrioid adenocarcinoma, others include a broader range of Type 1 tumors, which might dilute genetic signals or necessitate larger sample sizes to detect associations within more narrowly defined subgroups.^[1]Moreover, the potential for misclassification, such as the inclusion of individuals with undiagnosed endometrial neoplasm in control groups, can weaken the statistical power of a study without necessarily leading to false-positive results.^[13]

Unaccounted Factors and Remaining Knowledge Gaps

Despite advances, a substantial portion of the genetic basis for endometrial neoplasm risk remains unexplained, often referred to as missing heritability. This can be attributed to a combination of a low inherited genetic component, the complex heterogeneity of tumors, and the subtle effects of many genetic variants that current study designs may not be adequately powered to detect.^[1] The limited number of genome-wide significant loci identified to date underscores this gap, with projections indicating that significantly larger cohorts are needed to uncover additional variants with even moderate effect sizes.^[1]Furthermore, while some studies adjust for known confounders like BMI, the broader influence of environmental factors and complex gene-environment interactions on endometrial neoplasm development is often not fully captured or explored. The reliance on genotyping arrays with targeted content rather than comprehensive genome-wide coverage, along with a lack of imputation in some datasets, may also mean that important genetic variations are missed, further contributing to the remaining knowledge gaps in the etiology of endometrial neoplasm.^[10]

Variants

Genetic variations play a crucial role in influencing an individual’s susceptibility to various diseases, including endometrial neoplasm. Among these, the variantrs4430796 in the HNF1Bgene stands out as a significant factor associated with endometrial cancer risk. TheHNF1B (Hepatocyte Nuclear Factor 1 Beta) gene encodes a transcription factor essential for the development of multiple organs, including the kidney, pancreas, and Müllerian ducts, and its dysregulation is linked to various pathologies. The G-allele of rs4430796 has been consistently associated with a reduced risk of endometrial cancer, particularly for tumors with endometrioid histology.^[9] This protective effect is substantial, with studies reporting odds ratios around 0.84 to 0.92 per G-allele.^[9] The variant is located within a region of strong linkage disequilibrium encompassing the first four exons of HNF1B on chromosome 17q12, suggesting that it may influence gene expression or function. While rs4430796 itself might not be the direct causal variant, HNF1Bis a known susceptibility gene for other cancers, such as ovarian and prostate cancer, with evidence of altered isoform usage in cancerous tissues, highlighting its broad importance in oncogenesis.^[1]Notably, this association with endometrial cancer risk appears independent of factors like body mass index or type 2 diabetes.^[9]Other genetic variants, while not as extensively detailed in current endometrial cancer studies, are found in genes involved in critical cellular processes that could indirectly influence neoplasm development. For instance,rs3184504 is located in a region encompassing ATXN2 (Ataxin 2) and SH2B3 (SH2B Adaptor Protein 3). SH2B3is an adaptor protein vital for cytokine signaling and immune cell regulation, and variants in this gene are often associated with autoimmune conditions, which can sometimes involve chronic inflammation, a known contributor to cancer risk.^[9] Similarly, rs17035310 is found near TET2 (Ten-Eleven Translocation Methylcytosine Dioxygenase 2), an enzyme crucial for DNA demethylation and epigenetic regulation. Dysregulation of TET2is frequently observed in various cancers, where altered epigenetic patterns can drive abnormal cell proliferation and differentiation, thereby potentially impacting endometrial neoplasm risk.^[1] Further variants are linked to genes with diverse roles in cell growth, signaling, and development. The intronic variant rs10457678 is located in ECT2L(Epithelial Cell Transforming 2 Like), a gene that encodes a guanine nucleotide exchange factor activating Rho GTPases. These GTPases are fundamental regulators of cell migration, growth, and cytoskeletal organization, pathways frequently altered in cancerous cells, suggesting a potential role for this variant in influencing tumor behavior.^[9] The intergenic variant rs1512436 is near LINC02719, a long intergenic non-coding RNA. LncRNAs are increasingly recognized for their regulatory functions in gene expression, chromatin remodeling, and various cellular processes, including tumorigenesis and metastasis, which could contribute to endometrial cancer progression.^[1] Other variants, such as rs4378954 in LSAMP (Limbic System-Associated Membrane Protein), rs12970291 near TSHZ1 (Teashirt Zinc Finger Homeobox 1) and SMIM21 (Small Integral Membrane Protein 21), rs2052678 in TMTC1 (Transmembrane and Tetratricopeptide Repeat Containing 1), rs6051080 in FAM182A (Family With Sequence Similarity 182 Member A), and rs76225372 between AIFM1P1 (Apoptosis Inducing Factor Mitochondrion Associated 1 Pseudogene 1) and MALRD1(MAL, T-cell differentiation protein-related gene 1), are associated with genes involved in broad cellular functions like neuronal adhesion, development, protein-protein interactions, and potentially cell cycle control. While direct links to endometrial neoplasm for these specific variants require further investigation, their presence in genes with fundamental biological roles implies potential subtle influences on cancer susceptibility through altered gene function or expression.^[9]

Key Variants

RS ID	Gene	Related Traits
rs4430796	HNF1B	type 2 diabetes mellitus prostate carcinoma prostate specific antigen amount endometrial neoplasm cancer
rs3184504	ATXN2, SH2B3	beta-2 microglobulin hemoglobin lung carcinoma, estrogen-receptor negative breast cancer, ovarian endometrioid carcinoma, colorectal cancer, prostate carcinoma, ovarian serous carcinoma, breast carcinoma, ovarian carcinoma, squamous cell lung carcinoma, lung adenocarcinoma platelet crit coronary artery disease
rs12970291	TSHZ1 - SMIM21	endometrial neoplasm
rs4378954	LSAMP	endometrial neoplasm
rs10457678	ECT2L	endometrial neoplasm
rs17035310	RNU6-351P - TET2	endometrial neoplasm prostate carcinoma
rs2052678	TMTC1	endometrial neoplasm
rs6051080	FAM182A	endometrial neoplasm
rs76225372	AIFM1P1 - MALRD1	endometrial neoplasm
rs1512436	LINC02719 - GUCY1A2	endometrial neoplasm

Epidemiological and Clinical Phenotypes

Endometrial neoplasm, characterized as a cancer of the uterine epithelial lining, stands as the most common gynecological malignancy in developed countries and ranks as the fourth most prevalent cancer among women in the United States.^[1]The clinical presentation of this disease encompasses diverse phenotypes, with Type I endometrial cancer and the endometrioid subtype being frequently studied classifications in genetic research.^{[1], [9]}While specific symptomatic details are not consistently delineated in genetic studies, epidemiological data confirm its occurrence across various age groups, including younger women, and a notable association with factors such as postmenopausal unopposed estrogen use.^{[14], [15]}This inherent heterogeneity in presentation underscores the complex interplay of factors driving disease manifestation and progression, informing tailored diagnostic and prognostic strategies.

Genetic and Environmental Risk Indicators

A significant indicator of susceptibility to endometrial neoplasm is a family history of the disease, which highlights the role of inherited genetic factors in its development.^{[1], [7]} Genome-wide association studies have identified specific genetic variants associated with an increased risk, such as those located near the HNF1B gene, notably rs4430796 , which show a significant correlation with endometrial cancer, particularly of the endometrioid histological type.^{[1], [9]} Furthermore, the rs10917151 variant near CDC42/WNT4has also been linked to endometrial cancer risk.^[13]Beyond genetic predispositions, several environmental and physiological factors contribute to the variability in disease risk, including an elevated body mass index (BMI).^{[16], [17]} and early age at menarche.^[18] These diverse risk indicators serve as crucial red flags, informing comprehensive patient assessment and guiding differential diagnosis to identify individuals at heightened risk.

Biomarker-Based Diagnostic Approaches

The detection and diagnosis of endometrial neoplasm are increasingly augmented by the assessment of various molecular biomarkers. A multimarker panel, including prolactin, has demonstrated high diagnostic power for the early detection of endometrial cancer.^[19] These objective approaches offer substantial diagnostic value, particularly for identifying neoplastic changes in the uterine lining at early stages or in situations where overt clinical symptoms may be subtle or not yet apparent. The utility of such biomarker panels extends to contributing to differential diagnosis and serving as prognostic indicators, facilitating timely clinical intervention and improved patient outcomes.

Causes of Endometrial Neoplasm

Endometrial neoplasm, the most common gynecological malignancy in developed countries, arises from a complex interplay of genetic predispositions, hormonal imbalances, environmental exposures, and molecular alterations. Understanding these diverse causal pathways is crucial for risk assessment and prevention strategies.

Genetic Predisposition and Inherited Risk

Familial clustering of endometrial cancer (EC) strongly indicates a role for inherited genetic factors in its development.^[1] Genome-wide association studies (GWAS) have identified common susceptibility polymorphisms that contribute to risk. Notably, a common variant, rs4430796 , located within the HNF1B gene on chromosome 17q12, is significantly associated with a reduced risk of EC, particularly for cases with endometrioid histology.^[9] Other identified common susceptibility loci include those near SH2B3 and TSHZ1.^[10] Beyond common variants, Mendelian forms of EC exist, often characterized by genetic instability of microsatellites.^[20] These forms are frequently linked to mutations in DNA mismatch repair genes, such as PMS homologues and mutLhomologues, which are also implicated in hereditary nonpolyposis colorectal cancer.^[3] Additionally, variants at the PRLRlocus have been suggested to influence EC risk by potentiating cellular proliferation and inhibiting chemotherapy-induced apoptosis in endometrial cancer cell lines.^[21]

Hormonal Dysregulation and Lifestyle Factors

A primary driver of endometrial neoplasm is prolonged exposure to unopposed estrogens, a condition where estrogen’s proliferative effects on the endometrium are not counterbalanced by progesterone.^[14]Estrogen actively stimulates the mitotic rate of endometrial tissue, leading to proliferation, while progesterone induces glandular and stromal differentiation, thereby mitigating estrogen’s growth-stimulatory effects.^[22]This hormonal imbalance can be exacerbated by various lifestyle factors.

Obesity and overweight status are significant and avoidable causes of endometrial cancer.^[23]Adipose tissue in obese individuals produces estrogen, contributing to a state of endogenous unopposed estrogen and consequently increased endometrial mitotic activity.^[24]Furthermore, medication effects, such as postmenopausal therapy with estrogens alone without concurrent progestogens, are known to increase the risk of endometrial carcinoma.^[15] Conversely, progestin therapy has been shown to reverse endometrial hyperplasia, highlighting the protective role of progesterone.^[25]

Molecular and Epigenetic Contributions

The development of endometrial neoplasm involves complex molecular alterations, including changes in DNA methylation patterns, which show differences between cancerous and non-cancerous endometrial tissues.^[26]These epigenetic modifications can influence gene expression without altering the underlying DNA sequence, potentially contributing to uncontrolled cell growth and survival. While specific early life influences are not extensively detailed, research indicates that factors like age at menarche are associated with cancer risk, suggesting that developmental timing can play a role in shaping an individual’s susceptibility to endometrial cancer later in life.^[18]Integrated genomic characterization efforts aim to comprehensively map these molecular changes to better understand the pathogenesis of endometrial carcinoma.^[26]

Gene-Environment Interactions

Endometrial neoplasm risk is further modulated by interactions between genetic predispositions and environmental or lifestyle factors. While genetic variants in genes involved in sex steroid hormone metabolism, such asCYP19A1(aromatase), have been investigated for their association with EC risk, these single nucleotide polymorphisms (SNPs) explain only a small fraction of the overall genetic risk.^[27]This suggests that the impact of genetic variants may be significantly influenced by environmental triggers. For example, genetic predispositions could interact with exposure to unopposed estrogens from exogenous hormone therapy or obesity-related endogenous estrogen production, collectively contributing to an individual’s overall risk profile for endometrial neoplasm.

Biological Background of Endometrial Neoplasm

Endometrial cancer (EC) is a neoplasm originating from the epithelial lining of the uterus, known as the endometrium. It represents the most common gynecological malignancy in developed countries and is the fourth most prevalent cancer among women in the United States, primarily affecting postmenopausal individuals and those of European ancestry. The disease is broadly categorized into two main subtypes: Type I ECs, which are predominantly endometrioid adenocarcinomas and account for 80-90% of cases, and Type II ECs, comprising serous and clear cell carcinomas, making up the remaining 10-20%.^[1]A strong association exists between EC risk and a Western lifestyle, with incidence rates observed to be up to tenfold higher in industrialized Western countries compared to regions in Asia or rural Africa.^[28]Furthermore, a family history of EC significantly elevates an individual’s risk, indicating a role for inherited genetic factors in disease susceptibility.^[6]

Hormonal Control of Endometrial Growth

The normal growth and function of the endometrium are tightly regulated by a delicate balance of steroid hormones, primarily estrogen and progesterone. Estrogen plays a critical role in stimulating the proliferation of endometrial tissue, a process characteristic of the follicular phase of the menstrual cycle when progesterone levels are low.^[22] Conversely, progesterone acts to counteract these growth-stimulatory effects by promoting glandular and stromal differentiation within the endometrium.^[29]This intricate interplay is central to the “unopposed estrogen hypothesis,” which posits that prolonged exposure to estrogen without sufficient progesterone to induce differentiation leads to abnormally high mitotic rates and endometrial hyperplasia, significantly increasing the risk of developing endometrial neoplasia.^[15]The clinical relevance of this hormonal regulation is underscored by therapeutic and epidemiological observations. Endometrial hyperplasia, a precursor to cancer, can often be reversed through progestin therapy.^[25]Moreover, the use of oral contraceptives, which typically combine estrogen and progestin, is associated with a reduced risk of endometrial cancer.^[14]This emphasizes the critical role of progesterone in maintaining endometrial homeostasis and preventing uncontrolled cellular proliferation, highlighting the disruption of this balance as a fundamental pathophysiological process in the development of endometrial neoplasm.

Molecular Pathways and Cellular Dysregulation

Beyond the primary sex steroid hormones, a network of molecular signaling pathways and key biomolecules contributes to the regulation of endometrial cell growth and differentiation, and their dysregulation can drive neoplastic transformation. For instance, prolactin signaling, mediated through its receptor PRLR, has been observed to be elevated in endometrial tumors compared to non-cancerous tissue.^[21] This signaling pathway is known to potentiate cellular proliferation and inhibit chemotherapy-induced apoptosis in EC cell lines, suggesting its involvement in tumor progression and resistance.^[21] Other critical signaling factors and receptors include WNT4, a secreted signaling molecule essential for female sex development and the regulation of postnatal uterine development, as well as progesterone signaling during decidualization.^[30] The gene GREB1is an early response gene within the estrogen receptor (ER)-regulated pathway, promoting the growth of various hormone-dependent cancer cells.^[31]The estrogen receptor alpha, encoded byESR1, is a ligand-activated nuclear receptor that directly regulates cell proliferation in the uterus.^[32] Additionally, the FSHBgene, encoding the biologically active subunit of follicle-stimulating hormone, also plays a role in reproductive physiology.^[33] Cellular functions can also be impacted by small GTPases like CDC42, which has been implicated in the risk of endometriosis, a condition linked to ectopic endometrial-like tissue.^[34]

Genetic Basis of Endometrial Cancer

The predisposition to endometrial cancer has a significant genetic component, as evidenced by the increased risk observed in women with a family history of the disease.^[1]Efforts to identify specific genetic mechanisms have included investigating polymorphic variants in genes involved in sex steroid hormone metabolism, such asCYP19A1 (aromatase).^[35]While some studies suggest an association between single nucleotide polymorphisms (SNPs) in these genes and EC risk, they collectively explain only a small fraction of the overall genetic risk.^[35] Genome-wide association studies (GWAS) have been instrumental in identifying novel genetic loci associated with EC susceptibility. One such locus, identified at a genome-wide significance level, is located within the HNF1B gene on chromosome 17.^[9] Specifically, the common variant rs4430796 in HNF1B has been consistently associated with a reduced risk of EC.^[9]Beyond specific SNPs, broader genetic alterations are also implicated, including genetic instability of microsatellites, which is a recognized feature in endometrial carcinoma.^[20]The integrated genomic characterization of endometrial carcinoma further reveals a complex landscape of genetic changes contributing to disease development.^[26]

Systemic Influences and Risk Factors

Endometrial cancer, as a neoplasm of the uterine epithelial lining, also demonstrates a strong link to systemic and environmental factors, alongside its intrinsic biological mechanisms. As noted, the disease primarily affects postmenopausal women and is more prevalent in those of European ancestry.^[1] The estimated lifetime risk for women developing EC in the USA is approximately 1 in 38.^[36]A significant epidemiological observation is the strong association between a Western lifestyle and an increased incidence of EC, with rates notably higher in industrialized Western countries compared to other regions.^[28]This suggests that environmental exposures, dietary patterns, and lifestyle choices may interact with an individual’s genetic predisposition and hormonal milieu to influence disease development. The interplay between these systemic factors and the underlying molecular and genetic pathways ultimately contributes to the overall risk and progression of endometrial neoplasm.

Hormonal Dysregulation and Receptor-Mediated Pathways

Endometrial neoplasm is profoundly influenced by the dysregulation of hormonal signaling, primarily involving estrogen and progesterone. The estrogen receptor alpha (ESR1), located at 6q25.2, is a ligand-activated nuclear receptor crucial for regulating cell proliferation within the uterus.^[37]Unopposed estrogen exposure, without sufficient progesterone, is a central mechanism driving increased endometrial mitotic rate and subsequently elevating the risk of endometrial cancer.^[24]Progestins typically counteract estrogen-induced proliferation, highlighting the critical balance maintained by cytoplasmic progesterone and estradiol receptors in healthy endometrial tissue, which becomes disrupted in hyperplastic and carcinomatous states.^[29] Genetic variants in genes like CYP19A1, which is involved in estrogen metabolism, are also linked to endometrial cancer risk, further underscoring the importance of estrogen synthesis and breakdown pathways.^[27]Beyond direct receptor activation, several downstream effectors and regulatory genes contribute to the estrogen-driven proliferative environment.GREB1at 2p25.1, for instance, acts as an early response gene in the estrogen receptor-regulated pathway, actively promoting cell growth.^[37] Similarly, WNT4 at 1p36.12, a secreted signaling factor, plays a role in female sex development and regulates postnatal uterine development and progesterone signaling during decidualization.^[37]Alterations in these pathways can lead to aberrant cellular expansion. Furthermore, the follicle-stimulating hormone, encoded byFSHB at 11p14.1, contributes to the hormonal milieu that influences endometrial cell behavior.^[37]The intricate interaction between estrogen receptor alpha and heat shock proteins likeHsp70 also represents a post-translational regulatory mechanism impacting receptor stability and function, thereby influencing the overall hormonal responsiveness of endometrial cells.^[38]

Intracellular Signaling Networks Driving Proliferation

Beyond hormonal receptors, several intracellular signaling cascades are aberrantly activated or suppressed, driving the neoplastic process in the endometrium. The WNT/β-catenin pathway, for example, is critical for normal development but its paracrine activation in uterine leiomyoma stem cells can promote tumor growth.^[38] This pathway often involves frizzled class receptor 7 (FZD7), whose expression can be upregulated by SIRT1 and β-catenin, contributing to uncontrolled cell proliferation.^[11]Additionally, genome-wide genetic analyses highlight the involvement of the mitogen-activated protein kinase (MAPK) signaling pathway in the pathogenesis of related gynecologic conditions like endometriosis, suggesting its potential role in endometrial neoplasia through regulating cell growth, differentiation, and survival.^[39] The transforming growth factor beta (TGF-β) pathway also plays a complex role, influencing cell growth and differentiation, and its dysregulation is implicated in the biology of uterine fibroids.^[38] Another critical pathway, the SRF-FOS-JUNBpathway, is found to be downregulated in conditions like fumarate hydratase deficiency and uterine leiomyomas, indicating its importance in maintaining cellular homeostasis and preventing abnormal growth.^[38] These pathways are not isolated but engage in complex crosstalk, forming intricate networks that dictate cellular fate. For instance, the HMGA2 gene interacts with the p19Arf-TP53-CDKN1A axis, maintaining a delicate balance essential for normal cell growth, which if disrupted, can contribute to the development of uterine leiomyomas and potentially endometrial neoplasia.^[38]

Genomic Integrity and Epigenetic Control in Endometrial Neoplasia

Maintenance of genomic integrity is paramount in preventing neoplasia, and its disruption is a key mechanism in endometrial cancer. Genetic instability of microsatellites, often seen in endometrial carcinoma, indicates a failure in DNA mismatch repair mechanisms, leading to an accumulation of mutations that drive tumor progression.^[20] Specific genetic variants also confer risk, such as those in HNF1B, which have been associated with endometrial cancer risk.^[27]Furthermore, single nucleotide polymorphisms (SNPs) at loci like 1p36.12 associated with endometriosis risk are suggested to act throughCDC42, a small GTPase of the Rho family, impacting cellular organization and signaling.^[37]Epigenetic mechanisms, which modulate gene expression without altering the underlying DNA sequence, also play a significant role. These include modifications like DNA methylation or histone alterations. Studies in other cancers highlight the emergence of epigenetic biomarkers such asC11orf87 for gastrointestinal cancers.^[12] The interplay between SIRT1 and β-catenin in regulating FZD7 expression also exemplifies how post-translational modifications (via deacetylase SIRT1) can influence critical signaling pathways, impacting gene regulation and cellular proliferation.^[11] Additionally, long noncoding RNAs, such as MYOSLID, which is serum response factor-dependent, can amplify differentiation programs, suggesting their potential involvement in regulating cell fate and their dysregulation in neoplasia.^[38]

Metabolic Reprogramming and Pathway Crosstalk

Metabolic pathways are increasingly recognized as crucial drivers of cancer, with their dysregulation contributing significantly to endometrial neoplasia. Hormone metabolism, particularly the synthesis and breakdown of estrogens, is a key area, with meta-analyses identifying novel genetic loci associated with endometriosis that highlight genes involved in these processes.^[39]This metabolic susceptibility contributes to the overall hormonal imbalance that fuels endometrial cell proliferation. Furthermore, broader metabolic factors, such as overweight and obesity, are established avoidable causes of cancer in general, including endometrial cancer, implying systemic metabolic dysregulation that impacts cellular energy balance and nutrient availability.^[23] The intricate crosstalk between various signaling pathways and metabolic processes forms a complex network that governs cellular behavior. For instance, the ERαpathway, while directly hormonal, also influences broader cellular metabolism. Estrogen-related receptor alpha has been identified as a regulator of renal sodium and potassium homeostasis and the renin-angiotensin pathway, indicating its involvement in metabolic and systemic regulation beyond direct reproductive functions.^[12]There is also evidence of common genetic origins and overlapping pathways between endometrial cancer, uterine leiomyomata, and endometriosis.^[37]These shared susceptibilities underscore a systems-level integration where dysregulation in one pathway or cell type can have emergent properties across related tissues, emphasizing the need for an integrative understanding of these network interactions in disease pathogenesis.

Risk Stratification and Prevention

Endometrial neoplasm is the most prevalent gynecological malignancy in developed countries, primarily affecting postmenopausal women of European ancestry, with an estimated lifetime risk of 1 in 38 in the USA.^[1]Clinical risk stratification relies on identifying established epidemiological factors, including advanced age, Western lifestyle, high body mass index (BMI), and early age at menarche.^[1] Hormonal influences are also critical, with prolonged exposure to unopposed estrogens significantly increasing risk, while oral contraceptive use has been shown to reduce it.^[15]Understanding these factors is crucial for identifying high-risk individuals and implementing targeted prevention strategies, such as lifestyle modifications and careful management of hormone replacement therapy.

Genetic predispositions further refine risk stratification and offer avenues for personalized prevention. Genome-wide association studies (GWAS) have identified specific loci associated with endometrial neoplasm risk, such as a common variant at theHNF1B locus, rs4430796 , which is consistently associated with reduced risk, particularly for the endometrioid histologic subtype.^[9] Additionally, common susceptibility polymorphisms near SH2B3 and TSHZ1have been identified, suggesting shared genetic origins with colorectal cancer.^[10] These genetic insights, alongside epidemiological data, contribute to a more comprehensive risk assessment, paving the way for targeted screening or preventive interventions in genetically susceptible populations.

Molecular Markers and Prognostic Implications

Integrated genomic characterization of endometrial carcinoma offers a deeper understanding of disease biology and holds promise for predicting clinical outcomes.^[26] The genetic variant rs4430796 within the HNF1B gene not only influences risk but also exhibits a stronger protective effect in cases with endometrioid histology.^[9] This differential association by histologic subtype underscores the potential for genetic markers to inform prognosis and guide tailored clinical pathways, as Type I endometrioid adenocarcinomas generally have a better prognosis than Type II serous or clear cell carcinomas.^[1] Furthermore, molecular pathways such as prolactin signaling, mediated by PRLR, have been implicated in tumor progression. Research indicates that PRLRsignaling can enhance proliferation and inhibit chemotherapy-induced apoptosis in endometrial cancer cell lines.^[21] This suggests that variations in the PRLRlocus or its expression could serve as predictive markers for disease aggressiveness or response to specific chemotherapeutic regimens, moving towards personalized medicine approaches where treatment selection is optimized based on an individual’s molecular profile.^[1]Developing a multi-marker panel that includes such molecular insights, alongside established tumor markers, could enhance the predictive power for disease progression and recurrence.^[19]

Comorbidities and Therapeutic Considerations

Endometrial neoplasm frequently co-occurs with or shares genetic underpinnings with other gynecological conditions, which has significant implications for comprehensive patient care. Epidemiological and genomic analyses reveal shared genetic origins and associations between endometrial neoplasm, endometriosis, and ovarian cancer.^[40]Similarly, uterine leiomyomata share genetic origins with endometriosis, and a causal effect of genetic predisposition to gain muscle mass on leiomyomata has been observed.^[37]Recognizing these overlapping phenotypes allows for a more holistic approach to patient management, particularly in individuals presenting with a history of these related conditions, by prompting heightened vigilance for endometrial neoplasm development.

Therapeutic strategies and monitoring protocols are directly influenced by these clinical associations and the underlying hormonal milieu. The presence of cytoplasmic progesterone and estradiol receptors in endometrial tissues has significant therapeutic implications, guiding the use of hormonal therapies.^[25]Progestins, known to regulate cellular proliferation, are often utilized in treatment or prevention settings, contrasting with the increased risk associated with unopposed estrogen therapy.^[29] For monitoring, a multi-marker panel, which has shown high diagnostic power, including markers like prolactin, can be employed for early detection or surveillance in at-risk populations or post-treatment settings.^[19]

Frequently Asked Questions About Endometrial Neoplasm

These questions address the most important and specific aspects of endometrial neoplasm based on current genetic research.

---

1. My aunt had this; am I also at risk?

Yes, a family history significantly increases your risk, suggesting inherited predispositions. If close relatives like your aunt had it, especially if they were younger, you might have a higher chance due to shared genetic factors.

2. Why did my cousin get this cancer so young?

For some, particularly those with a condition called Lynch syndrome caused by inherited changes in certain DNA repair genes, the disease can appear about 15 years earlier than in the general population. This genetic predisposition significantly increases risk.

3. My family has a history of colon cancer; does that matter for me?

Yes, it definitely can. Lynch syndrome, which is linked to a very high lifetime risk of endometrial cancer, is also known as Hereditary Nonpolyposis Colorectal Cancer (HNPCC). If this syndrome runs in your family, your risk for both cancers is substantially elevated.

4. My whole family is heavy, and some had this cancer. Is it just weight?

While obesity is a known risk factor, familial clustering of endometrial cancer has been observed even when accounting for weight. This suggests there might be underlying inherited genetic factors at play in your family, beyond just lifestyle.

5. Could a DNA test help me prevent this cancer?

For some, yes. If you have a strong family history, especially of early-onset cases or Lynch syndrome, genetic testing can identify specific inherited mutations. This knowledge helps you and your doctors develop personalized screening and prevention strategies.

6. Are there any genes that actually lower my risk?

Interestingly, yes. Research has identified certain common genetic variants, like one in the HNF1Bgene, that are associated with a significantly reduced risk of endometrial cancer. This gene encodes a transcription factor involved in regulating gene expression in your body.

7. I’m not European; does my background change my risk?

Research has primarily focused on populations of European ancestry, and some genetic findings may not apply universally to other ethnic backgrounds. More studies are needed across diverse ancestries to fully understand how genetic risk factors vary.

8. If nobody in my family has it, am I safe?

Most cases of endometrial cancer are sporadic, meaning they don’t have a strong inherited genetic cause, and a twin study even suggested a low genetic contribution in these instances. While your risk is lower without a family history, other environmental factors still play a role.

9. Knowing my genetics, what can I do differently?

If you have identified genetic predispositions, such as Lynch syndrome, your lifetime risk can be substantially higher (50-60% versus 2-3% in the general population). Knowing this allows for earlier and more frequent screening, and discussions about preventative measures with your doctor.

10. My sister and I live similar lives, why is my risk higher?

Even with similar lifestyles, individual genetic predispositions can lead to different risks. While many cases are sporadic, studies show a notable genetic component, especially in younger women, and familial clustering can occur. Your unique genetic makeup might make you more susceptible.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] De Vivo I et al. “Genome-wide association study of endometrial cancer in E2C2.” Hum Genet. 2014;133:211–224.

[2] Robboy, Stanley, et al. Robboy’s Pathology of the Female Reproductive Tract. Expert Consult, 2nd Edn. Churchill Livingstone, 2009.

[3] Nicolaides, NC et al. “Mutations of two PMS homologues in hereditary nonpoly­.” Science, 1994.

[4] Peltomaki, P et al. “Genetic mapping of a locus predisposing to human colorectal cancer.”Science, 1993.

[5] Aaltonen, LA et al. “Clues to the pathogenesis of familial colorectal cancer.”Science, 1993.

[6] Gruber, SB, and Thompson WD. “A population-based study of endometrial cancer and familial risk in younger women.”Cancer Epidemiol Biomarkers Prev (1996) 5:411–417.

[7] Seger, H. M., et al. “Familial clustering of endometrial cancer in a well-defined population.”Gynecol Oncol, vol. 122, 2011, pp. 75-78.

[8] Lichtenstein, Paul, et al. “Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland.”New England Journal of Medicine, vol. 343, no. 2, 2000, pp. 78-86.

[9] Spurdle AB et al. “Genome-wide association study identifies a common variant associated with risk of endometrial cancer.” Nat Genet. 2011;43:353–357.

[10] Cheng, T. H. et al. “Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer nearSH2B3 and TSHZ1.” Sci Rep, 2017.

[11] Wu X et al. “A comprehensive genome-wide cross-trait analysis of sexual factors and uterine leiomyoma.” PLoS Genet. 2024;20:e1011195.

[12] Kim J et al. “Genome-wide meta-analysis identifies novel risk loci for uterine fibroids within and across multiple ancestry groups.” Nat Commun. 2024;15:1034.

[13] Rafnar, T., et al. “Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits.”Nat Commun, 2019, PMID: 30194396.

[14] Henderson, B. E., et al. “The epidemiology of endometrial cancer in young women.”Br J Cancer, vol. 47, 1983, pp. 749-756.

[15] Herrinton, L. J., and N. S. Weiss. “Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma.”Ann Epidemiol, vol. 3, 1993, pp. 308-318.

[16] Renehan, A. G., et al. “Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.”Lancet (Lond, Engl), vol. 371, 2008, pp. 569–78.

[17] Bhaskaran, K et al. “Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults.”Lancet (Lond, Engl), vol. 384, 2014, pp. 755–65.

[18] Day, F. R., et al. “Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk.”Nat Genet, vol. 49, 2017, pp. 834-41.

[19] Yurkovetsky, Z., et al. “Development of multi-marker panel for early detection of endometrial cancer. High diagnostic power of prolactin.”Gynecol Oncol, vol. 107, 2007, pp. 58-65.

[20] Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. “Genetic instability of microsatellites in endometrial carcinoma.” Cancer Res. 1993;53:5100–5103.

[21] Levina, Viktoriya V., et al. “Prolactin enhances proliferation and inhibits chemotherapy-induced apoptosis of human endometrial carcinoma cells.”Gynecologic Oncology, vol. 115, no. 2, 2009, pp. 272-277.

[22] Ferenczy, A et al. “Proliferation kinetics of human endometrium during the normal menstrual cycle.” Am J Obstet Gynecol, 1979.

[23] Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. “Overweight as an avoidable cause of cancer in Europe.” Int J Cancer. 2001;91:421–430.

[24] Key TJ, Pike MC. “The dose–effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk.” Br J Cancer. 1988;57:205–212.

[25] Ehrlich CE, Young PC, Cleary RE. “Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications.” Am J Obstet Gynecol. 1981;141:539–546.

[26] Kandoth, C et al. “Integrated genomic characterization of endometrial carci.” Cell, 2013.

[27] Setiawan VW et al. “HNF1B and endometrial cancer risk: results.” PLoS ONE. 2012;7:e30390.

[28] Pisani, P. et al. “Overweight as an avoidable cause of cancer in Europe.”Int J Cancer (1993) 91:421–430.

[29] Clarke CL, Sutherland RL. “Progestin regulation of cellular proliferation.” Endocr Rev. 1990;11:266–301.

[30] Franco, HL. et al. “WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse.” FASEB J (2011) 25:1176–1187.

[31] Rae, JM. et al. “GREB 1 is a critical regulator of hormone dependent breast cancer growth.”Breast Cancer Res Treat (2005) 92:141–149.

[32] Bondesson, M. et al. “Estrogen receptor signaling during vertebrate development.”Biochim Biophys Acta (2015) 1849:142–151.

[33] Layman, LC. et al. “Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene.”N Engl J Med (1997) 337:607–611.

[34] Powell, JE. et al. “Endometriosis risk alleles at 1p36.12 act through inverse regulation of CDC42 and LINC00339.”Hum Mol Genet (2016) 25:5046–5058.

[35] Setiawan VW et al. “Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the epidemiology of endometrial cancer consortium.” Cancer Epidemiol Biomarkers Prev. 2009;18:242–247.

[36] American Cancer Society. “What are the key statistics for endometrial cancer?” (2013).

[37] Gallagher CS et al. “Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis.” Nat Commun. 2019;10:4837.

[38] Sliz E et al. “Evidence of a causal effect of genetic tendency to gain muscle mass on uterine leiomyomata.” Nat Commun. 2023;14:550.

[39] Masuda T et al. “GWAS of five gynecologic diseases and cross-trait analysis in Japanese.” Eur J Hum Genet. 2019;27:1894–1904.

[40] Lu, Yi, et al. “Shared genetics underlying epidemiological association between endometriosis and ovarian cancer.”Human Molecular Genetics, vol. 24, no. 20, 2015, pp. 5955-5964.